The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
Open accessAbstract
The outbreak of 2019-novel coronavirus disease (COVID-19) that is caused by SARS-CoV-2 has spread rapidly in China, and has developed to be a Public Health Emergency of International Concern. However, no specific antiviral treatments or vaccines are available yet. This work aims to share strategies and candidate antigens to develop safe and effective vaccines against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, mRNA and DNA vaccines may not be able to induce protective efficacy in humans after a single immunization since, similar to inactivated and recombinant subunit protein vaccines, they typically require multiple administrations over an extended period of time to become effective (19).”
From An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citationA new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Fiore, A. E., Shay, D. K., Broder, K. R., Iskander, J. K., Uyeki, T. M., Mootrey, G., Bresee, J. S., & Cox, N. S. (2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,006
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341
Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127
Coronavirus envelope protein: current knowledge
Schoeman, D., & Fielding, B. C. (2019) · Virology Journal · doi:10.1186/s12985-019-1182-0 · Cited by 2,149
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,640
Clinical characteristics of 2019 novel coronavirus infection in ChinaPreprint
Guan, W., Ni, Z., Hu, Y., et al. (2020) · medRxiv · doi:10.1101/2020.02.06.20020974 · Cited by 1,485
Return of the Coronavirus: 2019-nCoV
Gralinski, L. E., & Menachery, V. D. (2020) · Viruses · doi:10.3390/v12020135 · Cited by 1,348
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yü, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,292
A decade after SARS: strategies for controlling emerging coronaviruses
Graham, R. L., Donaldson, E., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 689
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W., Huang, Y., Roberts, A., Murphy, B., Subbarao, K., & Nabel, G. (2004) · Nature · doi:10.1038/nature02463 · Cited by 688
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Bukreyev, A. A., Lamirande, E. W., Buchholz, U. J., Vogel, L., Elkins, W. R., Claire, M. S., Murphy, B. R., Subbarao, K., & Collins, P. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16501-x · Cited by 256
Jiang, S., He, Y., & Liu, S. (2005) · Emerging infectious diseases · doi:10.3201/1107.050219 · Cited by 214
Roper, R. L., & Rehm, K. E. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.43 · Cited by 183
Regla-Nava, J. Á., Nieto-Torres, J. L., Jiménez-Guardeño, J. M., Fernández‐Delgado, R., Fett, C., Castaño-Rodríguez, C., Perlman, S. M., Enjuanes, L., & DeDiego, M. L. (2015) · Journal of Virology · doi:10.1128/jvi.03566-14 · Cited by 153
Pre- and Posttreatment Chest CT Findings: 2019 Novel Coronavirus (2019-nCoV) Pneumonia
Duan, Y.-N., & Qin, J. (2020) · Radiology · doi:10.1148/radiol.2020200323 · Cited by 145
Yuan, J., Yang, J., Hu, Z., Yang, Y., Shang, W., Hu, Q., Zheng, Y., Peng, H., Zhang, X., Cai, X., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03893 · Cited by 54
Self-citationShi, S., PENG, J., Li, Y., Qin, C., LIANG, G., Xu, L., Yang, Y., Wang, J., & Sun, Q. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.11.005 · Cited by 41
Self-citationHe, W., Mullarkey, C. E., & Miller, M. S. (2015) · Methods · doi:10.1016/j.ymeth.2015.04.037 · Cited by 35
Protocol for Prevention and Control of COVID-19 (Edition 6)
Weekly, C. C., & National Health Commission of the People’s Republic of China (2020) · China CDC Weekly · doi:10.46234/ccdcw2020.082 · Cited by 34
Eyigün, C. P., Yilmaz, S., Gül, C., Şengül, A., HACIBEKTAŞOĞLU, A., & Thiel, D. H. V. (1998) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.1998.00106.x · Cited by 15
Cited by
Sorted by citations
COVID-19 Vaccine: A comprehensive status report
Kaur, S. P., & Gupta, V. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198114 · Cited by 870
The COVID-19 pandemic: a global health crisis
Pollard, C., Morran, M. P., & Nestor‐Kalinoski, A. L. (2020) · Physiological Genomics · doi:10.1152/physiolgenomics.00089.2020 · Cited by 554
Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza
Abbott, T. R., Dhamdhere, G. R., Liu, Y., Lin, X., Goudy, L., Zeng, L., Chemparathy, A., Chmura, S. A., Heaton, N. S., Debs, R. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.020 · Cited by 514
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
Wang, X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., Chu, Y., Feng, Y., & Wang, Q. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa721 · Cited by 363
Metadata
- Authors
- Shang, W., Yang, Y., Rao, Y., & Rao, X.
- Affiliations
- Army Medical University (CN)
- Venue
- npj Vaccines
- Published
- 2020-03-06
- Volume
- 5
- Issue
- 1
- Pages
- 18-18
- ISSN
- 2059-0105 (ISSN-L)
- PMC
- PMC7060195
- OpenAlex
- W3010200166
- Cited by
- 275
- References
- 25
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 18 · 2022: 41 · 2021: 72 · 2020: 132
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- npj Vaccines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, vaccine development, candidate antigens, viral vaccines, vaccination strategies, public health emergencies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
